Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Davidson, J. O., Bennet, L., Tan, S. & Gunn, A. J. When is a potential new neuroprotective treatment ready for translation? Pediatr. Res. https://doi.org/10.1038/s41390-019-0673-4 (2019).
Favié, L. M. A. et al. Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatr. Res. https://doi.org/10.1038/s41390-019-0587-1 (2019).
Peeters-Scholte, C. et al. Neuroprotection by selective nitric oxide synthase inhibition at 24 h after perinatal hypoxia-ischemia. Stroke 33, 2304–2310 (2002).
Zhu, C. et al. Nitrosylation precedes caspase-3 activation and translocation of apoptosis-inducing factor in neonatal rat cerebral hypoxia-ischaemia. J. Neurochem. 90, 462–471 (2004).
van den Tweel, E. R. et al. Long-term neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats. J. Cereb. Blood Flow Metab. 25, 67–74 (2005).
Nijboer, C. H. et al. Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J. Cereb. Blood Flow Metab. 27, 282–292 (2007).
Bjorkman, S. T. et al. Short-term dose-response characteristics of 2-iminobiotin immediately postinsult in the neonatal piglet after hypoxia-ischemia. Stroke 44, 809–811 (2013).
Zitta, K. et al. Insights into the neuroprotective mechanisms of 2-iminobiotin employing an in-vitro model of hypoxic-ischemic cell injury. Eur. J. Pharm. 792, 63–69 (2016).
Zitta, K. et al. 2-iminobiotin superimposed on hypothermia protects human neuronal cells from hypoxia-induced cell damage: an in vitro study. Front. Pharmacol. 8, 971 (2018).
van Hoogdalem, E. J. et al. First-in-human study of the safety, tolerability, pharmacokinetics and—preliminary dynamics of neuroprotectant 2-iminobiotin in healthy subjects. Curr. Clin. Pharmacol. https://doi.org/10.2174/1574884714666191017111109 (2019).
Nogawa, S., Zhang, F., Ross, M. E. & Iadecola, C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 15, 2746–2755 (1997).
Bel, F. V. & Groenendaal, F. Drugs for neuroprotection after birth asphyxia: pharmacologic adjuncts to hypothermia. Semin Perinatol. 40, 152–159 (2016).
Strzebonska, K. & Waligora, M. Umbrella and basket trials in oncology: ethical challenges. BMC Med. Ethics 20, 58 (2019).
Acknowledgements
The original study was supported by Neurophyxia BV with an unrestricted grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.M.P.C.D.P.-S., F.v.B. and F.G. are the inventors of 2-iminobiotin as a neuroprotective agent in neonates with hypoxic-ischemic encephalopathy. C.M.P.C.D.P.-S. and H.T. are shareholders and consultants of Neurophyxia BV. P.V. is employed at LAP&P Consultants BV. All other authors declare no conflicts of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Favié, L.M.A., Peeters-Scholte, C.M.P.C.D., Bakker, A. et al. Translation from animal to clinical studies, choosing the optimal moment. Pediatr Res 88, 836–837 (2020). https://doi.org/10.1038/s41390-020-0820-y
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41390-020-0820-y
